The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma.

Abstract

Interferon alpha-2a, which has antineoplastic, antiviral, immunomodulatory, and antiangiogenic effects, was evaluated in a prospective study, treating 10 lesions of patients with classical Kaposi's sarcoma. Ten patients received injections of interferon alpha-2a intralesionally in a dose of 3 million units three times weekly for 4 weeks, and in a variable dose for 4 more weeks. Two of the patients had a complete response, and in one of these, distant lesions also responded. Seven had a partial response, and one did not respond. The treatment was generally well tolerated. The results of our study support the use of interferon in the therapy of classical Kaposi's sarcoma, although it would appear that to achieve maximum efficacy, a longer period of treatment is needed.

• Authors: A Trattner, Z Reizis, M David, A Ingber, J Hagler, M Sandbank
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 129 Issue 5 Pg. 590-3 (Nov 1993) ISSN: 0007-0963 [Print] England
• PMID: 8251357 (Publication Type: Journal Article)

Chemical References

• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins

Topics

• Adult
• Aged
• Female
• Humans
• Injections, Intralesional
• Interferon alpha-2
• Interferon-alpha (administration & dosage, therapeutic use)
• Male
• Middle Aged
• Prospective Studies
• Recombinant Proteins
• Sarcoma, Kaposi (drug therapy)